| Name | Title | Contact Details |
|---|
Pinion is a business advisory provider, ‘U.S. Top 100 accounting firm, and global leader in food and agriculture consulting. With roots dating back to 1932, the firm has expanded upon traditional tax and accounting services to deliver increased value and growth for clients through its specialized advisory in the areas of sustainability, government affairs, farm programs, land/water management, financial management, succession planning, and business strategy – to name a few. Pinion provides insight and solutions for food and agriculture, biofuels, and manufacturing industries, as well as regionally-focused businesses. The firm serves domestic and international clientele from locations spanning the United States, Australia, and globally through partners and affiliates. Visit www.pinionglobal.com. *Attest services provided by KCoe Isom, LLP, a licensed CPA firm.
Focus on joint success We are one of the international market and technology leaders for innovative laser marking systems. As a global brand and technology center for laser marking solutions, we are part of the Product Quality and Identification segment of the publicly traded Veralto Corporation. FOBA is a leader in camera-based precision systems, machines and workflows for laser marking and engraving. We help our customers to ensure the traceability of their products, to protect their quality and brands, to design products and to respond to trends and regulations at an early stage – especially in our key markets of medical technology and the automotive, aerospace and electronics industries. With decades of laser application expertise, technology leadership in camera-assisted laser marking and consistent customer and service orientation, we can refer to several thousand successfully installed systems worldwide. https://www.fobalaser.com Imprint: https://www.fobalaser.com/legal-notice/ FOBA Laser Marking + Engraving Brand of ALLTEC Angewandte Laserlicht Technologie GmbH
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
HPI redefines what is possible with self-funded health plans. As a third-party administrator, we partner with health plan brokers and employers to provide innovative self-funding strategies and customized plans tailored to each clients needs and population. Our solutions give employers greater cost transparency and control, while elevating the member experience.